#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Stroke is a major cause of dementia , especially in the elderly .
2-1	16-22	Stroke	abstract	new	coref	2-3[3_0]
2-2	23-25	is	_	_	_	_
2-3	26-27	a	abstract[3]	giv[3]	coref	21-17[137_3]
2-4	28-33	major	abstract[3]	giv[3]	_	_
2-5	34-39	cause	abstract[3]	giv[3]	_	_
2-6	40-42	of	abstract[3]	giv[3]	_	_
2-7	43-51	dementia	abstract[3]|abstract	giv[3]|new	coref	3-4[5_0]
2-8	52-53	,	abstract[3]	giv[3]	_	_
2-9	54-64	especially	abstract[3]	giv[3]	_	_
2-10	65-67	in	abstract[3]	giv[3]	_	_
2-11	68-71	the	abstract[3]	giv[3]	_	_
2-12	72-79	elderly	abstract[3]	giv[3]	_	_
2-13	80-81	.	_	_	_	_

#Text=Specifically , the one-year post-stroke dementia ( PSD ) rates after first-ever and recurrent stroke are approximately 10 % and 30 % , respectively .
3-1	82-94	Specifically	_	_	_	_
3-2	95-96	,	_	_	_	_
3-3	97-100	the	abstract[7]	new[7]	coref	3-17[9_7]
3-4	101-109	one-year	abstract[5]|abstract[7]	giv[5]|new[7]	coref	4-4[14_5]
3-5	110-121	post-stroke	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
3-6	122-130	dementia	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
3-7	131-132	(	abstract[7]	new[7]	_	_
3-8	133-136	PSD	person|abstract[7]	new|new[7]	coref	24-11
3-9	137-138	)	abstract[7]	new[7]	_	_
3-10	139-144	rates	abstract[7]	new[7]	_	_
3-11	145-150	after	abstract[7]	new[7]	_	_
3-12	151-161	first-ever	abstract[7]|event[8]	new[7]|new[8]	coref	10-31[0_8]
3-13	162-165	and	abstract[7]|event[8]	new[7]|new[8]	_	_
3-14	166-175	recurrent	abstract[7]|event[8]	new[7]|new[8]	_	_
3-15	176-182	stroke	abstract[7]|event[8]	new[7]|new[8]	_	_
3-16	183-186	are	_	_	_	_
3-17	187-200	approximately	abstract[9]|abstract[10]	giv[9]|giv[10]	coref	3-17[10_9]
3-18	201-203	10	abstract[9]|abstract[10]	giv[9]|giv[10]	_	_
3-19	204-205	%	abstract[9]|abstract[10]	giv[9]|giv[10]	_	_
3-20	206-209	and	abstract[10]	giv[10]	_	_
3-21	210-212	30	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-22	213-214	%	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-23	215-216	,	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-24	217-229	respectively	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-25	230-231	.	_	_	_	_

#Text=Neuropathological studies into Alzheimer ’s disease ( AD ) have shown that AD pathology is often concomitant with ischemic lesions in the elderly .
4-1	232-249	Neuropathological	abstract[12]	new[12]	coref	24-30[161_12]
4-2	250-257	studies	abstract[12]	new[12]	_	_
4-3	258-262	into	abstract[12]	new[12]	_	_
4-4	263-272	Alzheimer	abstract[12]|person[13]|abstract[14]	new[12]|new[13]|giv[14]	appos	4-8[0_14]
4-5	273-275	’s	abstract[12]|person[13]|abstract[14]	new[12]|new[13]|giv[14]	_	_
4-6	276-283	disease	abstract[12]|abstract[14]	new[12]|giv[14]	_	_
4-7	284-285	(	_	_	_	_
4-8	286-288	AD	abstract	giv	coref	4-13
4-9	289-290	)	_	_	_	_
4-10	291-295	have	_	_	_	_
4-11	296-301	shown	_	_	_	_
4-12	302-306	that	_	_	_	_
4-13	307-309	AD	abstract|abstract[17]	giv|new[17]	coref|coref	5-35|6-11[35_17]
4-14	310-319	pathology	abstract[17]	new[17]	_	_
4-15	320-322	is	_	_	_	_
4-16	323-328	often	_	_	_	_
4-17	329-340	concomitant	_	_	_	_
4-18	341-345	with	_	_	_	_
4-19	346-354	ischemic	abstract[18]	new[18]	_	_
4-20	355-362	lesions	abstract[18]	new[18]	_	_
4-21	363-365	in	abstract[18]	new[18]	_	_
4-22	366-369	the	abstract[18]	new[18]	_	_
4-23	370-377	elderly	abstract[18]	new[18]	_	_
4-24	378-379	.	_	_	_	_

#Text=For instance , evidence from the Nun Study showed that lacunes increase the risk of clinical expression of cognitive impairment more than 20 times during early Braak stages that were yet sufficient to produce dementia symptoms .
5-1	380-383	For	_	_	_	_
5-2	384-392	instance	_	_	_	_
5-3	393-394	,	_	_	_	_
5-4	395-403	evidence	abstract[19]	new[19]	_	_
5-5	404-408	from	abstract[19]	new[19]	_	_
5-6	409-412	the	abstract[19]|abstract[21]	new[19]|new[21]	coref	18-1[106_21]
5-7	413-416	Nun	abstract[19]|person|abstract[21]	new[19]|new|new[21]	_	_
5-8	417-422	Study	abstract[19]|abstract[21]	new[19]|new[21]	_	_
5-9	423-429	showed	_	_	_	_
5-10	430-434	that	_	_	_	_
5-11	435-442	lacunes	substance	new	_	_
5-12	443-451	increase	_	_	_	_
5-13	452-455	the	abstract[23]	new[23]	coref	22-9[143_23]
5-14	456-460	risk	abstract[23]	new[23]	_	_
5-15	461-463	of	abstract[23]	new[23]	_	_
5-16	464-472	clinical	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-17	473-483	expression	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-18	484-486	of	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-19	487-496	cognitive	abstract[23]|abstract[24]|abstract[25]	new[23]|new[24]|new[25]	ana	6-1[0_25]
5-20	497-507	impairment	abstract[23]|abstract[24]|abstract[25]	new[23]|new[24]|new[25]	_	_
5-21	508-512	more	time[26]	new[26]	_	_
5-22	513-517	than	time[26]	new[26]	_	_
5-23	518-520	20	time[26]	new[26]	_	_
5-24	521-526	times	time[26]	new[26]	_	_
5-25	527-533	during	_	_	_	_
5-26	534-539	early	event[28]	new[28]	_	_
5-27	540-545	Braak	abstract|event[28]	new|new[28]	_	_
5-28	546-552	stages	event[28]	new[28]	_	_
5-29	553-557	that	event[28]	new[28]	_	_
5-30	558-562	were	event[28]	new[28]	_	_
5-31	563-566	yet	event[28]	new[28]	_	_
5-32	567-577	sufficient	event[28]	new[28]	_	_
5-33	578-580	to	event[28]	new[28]	_	_
5-34	581-588	produce	event[28]	new[28]	_	_
5-35	589-597	dementia	event[28]|abstract|abstract[30]	new[28]|giv|new[30]	coref	6-11
5-36	598-606	symptoms	event[28]|abstract[30]	new[28]|new[30]	_	_
5-37	607-608	.	_	_	_	_

#Text=It follows that vascular insults enhance the clinical expression of AD pathology .
6-1	609-611	It	abstract	giv	coref	13-11[82_0]
6-2	612-619	follows	_	_	_	_
6-3	620-624	that	_	_	_	_
6-4	625-633	vascular	abstract[32]	new[32]	_	_
6-5	634-641	insults	abstract[32]	new[32]	_	_
6-6	642-649	enhance	_	_	_	_
6-7	650-653	the	abstract[33]	new[33]	_	_
6-8	654-662	clinical	abstract[33]	new[33]	_	_
6-9	663-673	expression	abstract[33]	new[33]	_	_
6-10	674-676	of	abstract[33]	new[33]	_	_
6-11	677-679	AD	abstract[33]|abstract|abstract[35]	new[33]|giv|giv[35]	coref	7-1[36_0]
6-12	680-689	pathology	abstract[33]|abstract[35]	new[33]|giv[35]	_	_
6-13	690-691	.	_	_	_	_

#Text=Vascular dementia is more prevalent in men and in populations affected by cerebral small-vessel disease , including Asians , Hispanics , and Africans .
7-1	692-700	Vascular	abstract[36]	giv[36]	coref	7-13[39_36]
7-2	701-709	dementia	abstract[36]	giv[36]	_	_
7-3	710-712	is	_	_	_	_
7-4	713-717	more	_	_	_	_
7-5	718-727	prevalent	_	_	_	_
7-6	728-730	in	_	_	_	_
7-7	731-734	men	person	new	_	_
7-8	735-738	and	_	_	_	_
7-9	739-741	in	_	_	_	_
7-10	742-753	populations	person[38]	new[38]	_	_
7-11	754-762	affected	person[38]	new[38]	_	_
7-12	763-765	by	person[38]	new[38]	_	_
7-13	766-774	cerebral	person[38]|abstract[39]	new[38]|giv[39]	coref	15-12[0_39]
7-14	775-787	small-vessel	person[38]|abstract[39]	new[38]|giv[39]	_	_
7-15	788-795	disease	person[38]|abstract[39]	new[38]|giv[39]	_	_
7-16	796-797	,	person[38]	new[38]	_	_
7-17	798-807	including	person[38]	new[38]	_	_
7-18	808-814	Asians	person[38]|person	new[38]|new	_	_
7-19	815-816	,	person[38]	new[38]	_	_
7-20	817-826	Hispanics	person[38]|person	new[38]|new	_	_
7-21	827-828	,	person[38]	new[38]	_	_
7-22	829-832	and	person[38]	new[38]	_	_
7-23	833-841	Africans	person[38]|person	new[38]|new	_	_
7-24	842-843	.	_	_	_	_

#Text=The cholinergic system is distributed throughout the central nervous system , playing a role in neurotransmission and possibly mediating various neuroprotective functions .
8-1	844-847	The	abstract[43]	new[43]	_	_
8-2	848-859	cholinergic	abstract[43]	new[43]	_	_
8-3	860-866	system	abstract[43]	new[43]	_	_
8-4	867-869	is	_	_	_	_
8-5	870-881	distributed	_	_	_	_
8-6	882-892	throughout	_	_	_	_
8-7	893-896	the	place[44]	new[44]	_	_
8-8	897-904	central	place[44]	new[44]	_	_
8-9	905-912	nervous	place[44]	new[44]	_	_
8-10	913-919	system	place[44]	new[44]	_	_
8-11	920-921	,	_	_	_	_
8-12	922-929	playing	_	_	_	_
8-13	930-931	a	abstract[45]	new[45]	coref	15-3[86_45]
8-14	932-936	role	abstract[45]	new[45]	_	_
8-15	937-939	in	abstract[45]	new[45]	_	_
8-16	940-957	neurotransmission	abstract[45]|abstract	new[45]|new	coref	9-3[48_0]
8-17	958-961	and	_	_	_	_
8-18	962-970	possibly	_	_	_	_
8-19	971-980	mediating	_	_	_	_
8-20	981-988	various	abstract[47]	new[47]	_	_
8-21	989-1004	neuroprotective	abstract[47]	new[47]	_	_
8-22	1005-1014	functions	abstract[47]	new[47]	_	_
8-23	1015-1016	.	_	_	_	_

#Text=Furthermore , cholinergic neurotransmission regulates the immune response during inflammation , in a pathway that involves nicotinic acetylcholine receptors ( nAChRs ) and inhibits peripheral cytokine release .
9-1	1017-1028	Furthermore	_	_	_	_
9-2	1029-1030	,	_	_	_	_
9-3	1031-1042	cholinergic	abstract[48]	giv[48]	_	_
9-4	1043-1060	neurotransmission	abstract[48]	giv[48]	_	_
9-5	1061-1070	regulates	_	_	_	_
9-6	1071-1074	the	abstract[49]	new[49]	_	_
9-7	1075-1081	immune	abstract[49]	new[49]	_	_
9-8	1082-1090	response	abstract[49]	new[49]	_	_
9-9	1091-1097	during	abstract[49]	new[49]	_	_
9-10	1098-1110	inflammation	abstract[49]|abstract	new[49]|new	coref	11-4
9-11	1111-1112	,	_	_	_	_
9-12	1113-1115	in	_	_	_	_
9-13	1116-1117	a	abstract[51]	new[51]	_	_
9-14	1118-1125	pathway	abstract[51]	new[51]	_	_
9-15	1126-1130	that	abstract[51]	new[51]	_	_
9-16	1131-1139	involves	abstract[51]	new[51]	_	_
9-17	1140-1149	nicotinic	abstract[51]|abstract[53]	new[51]|new[53]	appos	9-21[0_53]
9-18	1150-1163	acetylcholine	abstract[51]|substance|abstract[53]	new[51]|new|new[53]	coref	10-10
9-19	1164-1173	receptors	abstract[51]|abstract[53]	new[51]|new[53]	_	_
9-20	1174-1175	(	abstract[51]	new[51]	_	_
9-21	1176-1182	nAChRs	abstract[51]|abstract	new[51]|giv	coref	10-19[62_0]
9-22	1183-1184	)	abstract[51]	new[51]	_	_
9-23	1185-1188	and	abstract[51]	new[51]	_	_
9-24	1189-1197	inhibits	abstract[51]	new[51]	_	_
9-25	1198-1208	peripheral	abstract[51]|event[56]	new[51]|new[56]	coref	10-25[63_56]
9-26	1209-1217	cytokine	abstract[51]|abstract|event[56]	new[51]|new|new[56]	_	_
9-27	1218-1225	release	abstract[51]|event[56]	new[51]|new[56]	_	_
9-28	1226-1227	.	_	_	_	_

#Text=In particular , the efferent vagus nerve may release acetylcholine ( Ach ) , which subsequently binds with macrophage receptors and therefore may inhibit the release of inflammatory factors after stroke .
10-1	1228-1230	In	_	_	_	_
10-2	1231-1241	particular	_	_	_	_
10-3	1242-1243	,	_	_	_	_
10-4	1244-1247	the	object[58]	new[58]	_	_
10-5	1248-1256	efferent	object[58]	new[58]	_	_
10-6	1257-1262	vagus	object|object[58]	new|new[58]	_	_
10-7	1263-1268	nerve	object[58]	new[58]	_	_
10-8	1269-1272	may	_	_	_	_
10-9	1273-1280	release	_	_	_	_
10-10	1281-1294	acetylcholine	substance	giv	appos	10-12
10-11	1295-1296	(	_	_	_	_
10-12	1297-1300	Ach	substance	giv	coref	17-3
10-13	1301-1302	)	_	_	_	_
10-14	1303-1304	,	_	_	_	_
10-15	1305-1310	which	_	_	_	_
10-16	1311-1323	subsequently	_	_	_	_
10-17	1324-1329	binds	_	_	_	_
10-18	1330-1334	with	_	_	_	_
10-19	1335-1345	macrophage	place|abstract[62]	new|giv[62]	_	_
10-20	1346-1355	receptors	abstract[62]	giv[62]	_	_
10-21	1356-1359	and	_	_	_	_
10-22	1360-1369	therefore	_	_	_	_
10-23	1370-1373	may	_	_	_	_
10-24	1374-1381	inhibit	_	_	_	_
10-25	1382-1385	the	event[63]	giv[63]	_	_
10-26	1386-1393	release	event[63]	giv[63]	_	_
10-27	1394-1396	of	event[63]	giv[63]	_	_
10-28	1397-1409	inflammatory	event[63]|abstract[64]	giv[63]|new[64]	_	_
10-29	1410-1417	factors	event[63]|abstract[64]	giv[63]|new[64]	_	_
10-30	1418-1423	after	_	_	_	_
10-31	1424-1430	stroke	event	giv	coref	15-10
10-32	1431-1432	.	_	_	_	_

#Text=In addition to inflammation , excitotoxicity and energy failure following cerebral ischemia may also initiate intracellular death pathways and oxidative stress ( OS ) .
11-1	1433-1435	In	_	_	_	_
11-2	1436-1444	addition	_	_	_	_
11-3	1445-1447	to	_	_	_	_
11-4	1448-1460	inflammation	abstract	giv	coref	24-25
11-5	1461-1462	,	_	_	_	_
11-6	1463-1477	excitotoxicity	event	new	_	_
11-7	1478-1481	and	_	_	_	_
11-8	1482-1488	energy	abstract|event[69]	new|new[69]	_	_
11-9	1489-1496	failure	event[69]	new[69]	_	_
11-10	1497-1506	following	event[69]	new[69]	_	_
11-11	1507-1515	cerebral	event[69]|abstract[70]	new[69]|new[70]	_	_
11-12	1516-1524	ischemia	event[69]|abstract[70]	new[69]|new[70]	_	_
11-13	1525-1528	may	_	_	_	_
11-14	1529-1533	also	_	_	_	_
11-15	1534-1542	initiate	_	_	_	_
11-16	1543-1556	intracellular	abstract[72]	new[72]	_	_
11-17	1557-1562	death	event|abstract[72]	new|new[72]	_	_
11-18	1563-1571	pathways	abstract[72]	new[72]	_	_
11-19	1572-1575	and	_	_	_	_
11-20	1576-1585	oxidative	abstract|abstract[74]	new|new[74]	appos	11-23[0_74]
11-21	1586-1592	stress	abstract[74]	new[74]	_	_
11-22	1593-1594	(	_	_	_	_
11-23	1595-1597	OS	abstract	giv	coref	12-8
11-24	1598-1599	)	_	_	_	_
11-25	1600-1601	.	_	_	_	_

#Text=The structural and functional changes caused by OS led to cholinergic and other cellular damage .
12-1	1602-1605	The	abstract[76]	new[76]	coref	24-35[162_76]
12-2	1606-1616	structural	abstract[76]	new[76]	_	_
12-3	1617-1620	and	abstract[76]	new[76]	_	_
12-4	1621-1631	functional	abstract[76]	new[76]	_	_
12-5	1632-1639	changes	abstract[76]	new[76]	_	_
12-6	1640-1646	caused	abstract[76]	new[76]	_	_
12-7	1647-1649	by	abstract[76]	new[76]	_	_
12-8	1650-1652	OS	abstract[76]|abstract	new[76]|giv	coref	14-8
12-9	1653-1656	led	_	_	_	_
12-10	1657-1659	to	_	_	_	_
12-11	1660-1671	cholinergic	abstract[78]	new[78]	coref	23-11[150_78]
12-12	1672-1675	and	abstract[78]	new[78]	_	_
12-13	1676-1681	other	abstract[78]	new[78]	_	_
12-14	1682-1690	cellular	abstract[78]	new[78]	_	_
12-15	1691-1697	damage	abstract[78]	new[78]	_	_
12-16	1698-1699	.	_	_	_	_

#Text=Cholinergic deficit further caused brain atrophy and finally resulted in cognitive impairment .
13-1	1700-1711	Cholinergic	abstract[79]	new[79]	_	_
13-2	1712-1719	deficit	abstract[79]	new[79]	_	_
13-3	1720-1727	further	_	_	_	_
13-4	1728-1734	caused	_	_	_	_
13-5	1735-1740	brain	object|event[81]	new|new[81]	_	_
13-6	1741-1748	atrophy	event[81]	new[81]	_	_
13-7	1749-1752	and	_	_	_	_
13-8	1753-1760	finally	_	_	_	_
13-9	1761-1769	resulted	abstract	new	coref|none	21-4[133_0]|13-9[0_133]
13-10	1770-1772	in	_	_	_	_
13-11	1773-1782	cognitive	abstract[82]	giv[82]	coref	18-18[112_82]
13-12	1783-1793	impairment	abstract[82]	giv[82]	_	_
13-13	1794-1795	.	_	_	_	_

#Text=Anticholinergic agents have been shown to regulate OS and alleviate apoptosis .
14-1	1796-1811	Anticholinergic	substance[83]	new[83]	_	_
14-2	1812-1818	agents	substance[83]	new[83]	_	_
14-3	1819-1823	have	_	_	_	_
14-4	1824-1828	been	_	_	_	_
14-5	1829-1834	shown	_	_	_	_
14-6	1835-1837	to	_	_	_	_
14-7	1838-1846	regulate	_	_	_	_
14-8	1847-1849	OS	abstract	giv	coref	15-17
14-9	1850-1853	and	_	_	_	_
14-10	1854-1863	alleviate	_	_	_	_
14-11	1864-1873	apoptosis	abstract	new	_	_
14-12	1874-1875	.	_	_	_	_

#Text=Therefore , a key role in the pathogenesis of stroke and dementia may be attributed to OS .
15-1	1876-1885	Therefore	_	_	_	_
15-2	1886-1887	,	_	_	_	_
15-3	1888-1889	a	abstract[86]	giv[86]	_	_
15-4	1890-1893	key	abstract[86]	giv[86]	_	_
15-5	1894-1898	role	abstract[86]	giv[86]	_	_
15-6	1899-1901	in	abstract[86]	giv[86]	_	_
15-7	1902-1905	the	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-8	1906-1918	pathogenesis	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-9	1919-1921	of	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-10	1922-1928	stroke	abstract[86]|abstract[87]|event	giv[86]|new[87]|giv	coref	18-23
15-11	1929-1932	and	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-12	1933-1941	dementia	abstract[86]|abstract[87]|abstract	giv[86]|new[87]|giv	coref	16-6[92_0]
15-13	1942-1945	may	_	_	_	_
15-14	1946-1948	be	_	_	_	_
15-15	1949-1959	attributed	_	_	_	_
15-16	1960-1962	to	_	_	_	_
15-17	1963-1965	OS	abstract	giv	_	_
15-18	1966-1967	.	_	_	_	_

#Text=Cholinergic dysfunction is related to vascular dementia .
16-1	1968-1979	Cholinergic	abstract[91]	new[91]	coref	21-8[135_91]
16-2	1980-1991	dysfunction	abstract[91]	new[91]	_	_
16-3	1992-1994	is	_	_	_	_
16-4	1995-2002	related	_	_	_	_
16-5	2003-2005	to	_	_	_	_
16-6	2006-2014	vascular	abstract[92]	giv[92]	coref	17-18[98_92]
16-7	2015-2023	dementia	abstract[92]	giv[92]	_	_
16-8	2024-2025	.	_	_	_	_

#Text=Specifically , Ach levels in the cerebrospinal fluid are up to 49 % lower in patients with small-vessel vascular dementia than in control patients , suggesting that cholinergic agents or cholinesterase inhibitors , both of which increase the Ach level , could be used to treat such patients .
17-1	2026-2038	Specifically	_	_	_	_
17-2	2039-2040	,	_	_	_	_
17-3	2041-2044	Ach	substance|abstract[94]	giv|new[94]	coref|coref	17-39|24-37[166_94]
17-4	2045-2051	levels	abstract[94]	new[94]	_	_
17-5	2052-2054	in	abstract[94]	new[94]	_	_
17-6	2055-2058	the	abstract[94]|substance[95]	new[94]|new[95]	_	_
17-7	2059-2072	cerebrospinal	abstract[94]|substance[95]	new[94]|new[95]	_	_
17-8	2073-2078	fluid	abstract[94]|substance[95]	new[94]|new[95]	_	_
17-9	2079-2082	are	_	_	_	_
17-10	2083-2085	up	abstract[96]	new[96]	_	_
17-11	2086-2088	to	abstract[96]	new[96]	_	_
17-12	2089-2091	49	abstract[96]	new[96]	_	_
17-13	2092-2093	%	abstract[96]	new[96]	_	_
17-14	2094-2099	lower	_	_	_	_
17-15	2100-2102	in	_	_	_	_
17-16	2103-2111	patients	person[97]	new[97]	_	_
17-17	2112-2116	with	person[97]	new[97]	_	_
17-18	2117-2129	small-vessel	person[97]|abstract[98]	new[97]|giv[98]	coref	22-12[0_98]
17-19	2130-2138	vascular	person[97]|abstract[98]	new[97]|giv[98]	_	_
17-20	2139-2147	dementia	person[97]|abstract[98]	new[97]|giv[98]	_	_
17-21	2148-2152	than	_	_	_	_
17-22	2153-2155	in	_	_	_	_
17-23	2156-2163	control	person[99]	new[99]	coref	17-47[105_99]
17-24	2164-2172	patients	person[99]	new[99]	_	_
17-25	2173-2174	,	_	_	_	_
17-26	2175-2185	suggesting	_	_	_	_
17-27	2186-2190	that	_	_	_	_
17-28	2191-2202	cholinergic	substance[100]	new[100]	_	_
17-29	2203-2209	agents	substance[100]	new[100]	_	_
17-30	2210-2212	or	_	_	_	_
17-31	2213-2227	cholinesterase	abstract|substance[102]	new|new[102]	coref|coref	22-3[140_102]|24-37[164_0]
17-32	2228-2238	inhibitors	substance[102]	new[102]	_	_
17-33	2239-2240	,	_	_	_	_
17-34	2241-2245	both	_	_	_	_
17-35	2246-2248	of	_	_	_	_
17-36	2249-2254	which	_	_	_	_
17-37	2255-2263	increase	_	_	_	_
17-38	2264-2267	the	abstract[104]	new[104]	_	_
17-39	2268-2271	Ach	substance|abstract[104]	giv|new[104]	coref	19-21
17-40	2272-2277	level	abstract[104]	new[104]	_	_
17-41	2278-2279	,	_	_	_	_
17-42	2280-2285	could	_	_	_	_
17-43	2286-2288	be	_	_	_	_
17-44	2289-2293	used	_	_	_	_
17-45	2294-2296	to	_	_	_	_
17-46	2297-2302	treat	_	_	_	_
17-47	2303-2307	such	person[105]	giv[105]	coref	18-15[111_105]
17-48	2308-2316	patients	person[105]	giv[105]	_	_
17-49	2317-2318	.	_	_	_	_

#Text=One pilot study showed that acetylcholinesterase ( AChE ) inhibitor promoted functional recovery in elderly patients with cognitive impairment who had suffered stroke .
18-1	2319-2322	One	abstract[106]	giv[106]	coref	25-14[176_106]
18-2	2323-2328	pilot	abstract[106]	giv[106]	_	_
18-3	2329-2334	study	abstract[106]	giv[106]	_	_
18-4	2335-2341	showed	_	_	_	_
18-5	2342-2346	that	_	_	_	_
18-6	2347-2367	acetylcholinesterase	substance|abstract[109]	new|new[109]	_	_
18-7	2368-2369	(	abstract[109]	new[109]	_	_
18-8	2370-2374	AChE	abstract|abstract[109]	new|new[109]	coref	19-9
18-9	2375-2376	)	abstract[109]	new[109]	_	_
18-10	2377-2386	inhibitor	abstract[109]	new[109]	_	_
18-11	2387-2395	promoted	_	_	_	_
18-12	2396-2406	functional	event[110]	new[110]	_	_
18-13	2407-2415	recovery	event[110]	new[110]	_	_
18-14	2416-2418	in	_	_	_	_
18-15	2419-2426	elderly	person[111]	giv[111]	coref	20-5[128_111]
18-16	2427-2435	patients	person[111]	giv[111]	_	_
18-17	2436-2440	with	person[111]	giv[111]	_	_
18-18	2441-2450	cognitive	person[111]|abstract[112]	giv[111]|giv[112]	_	_
18-19	2451-2461	impairment	person[111]|abstract[112]	giv[111]|giv[112]	_	_
18-20	2462-2465	who	person[111]|abstract[112]	giv[111]|giv[112]	_	_
18-21	2466-2469	had	person[111]|abstract[112]	giv[111]|giv[112]	_	_
18-22	2470-2478	suffered	person[111]|abstract[112]	giv[111]|giv[112]	_	_
18-23	2479-2485	stroke	person[111]|abstract[112]|event	giv[111]|giv[112]|giv	coref	20-5
18-24	2486-2487	.	_	_	_	_

#Text=In a rat model of chronic ischemic , AChE activity was slightly decreased in the frontal cortex , but muscarinic acetylcholine receptor M1 was gradually depleted in cerebral cortex , striatum and hippocampus that are involved in cognitive function .
19-1	2488-2490	In	_	_	_	_
19-2	2491-2492	a	abstract[115]	new[115]	_	_
19-3	2493-2496	rat	animal|abstract[115]	new|new[115]	_	_
19-4	2497-2502	model	abstract[115]	new[115]	_	_
19-5	2503-2505	of	abstract[115]	new[115]	_	_
19-6	2506-2513	chronic	abstract[115]|abstract[116]	new[115]|new[116]	_	_
19-7	2514-2522	ischemic	abstract[115]|abstract[116]	new[115]|new[116]	_	_
19-8	2523-2524	,	_	_	_	_
19-9	2525-2529	AChE	abstract|abstract[118]	giv|new[118]	coref|coref	20-9|20-8[130_118]
19-10	2530-2538	activity	abstract[118]	new[118]	_	_
19-11	2539-2542	was	_	_	_	_
19-12	2543-2551	slightly	_	_	_	_
19-13	2552-2561	decreased	_	_	_	_
19-14	2562-2564	in	_	_	_	_
19-15	2565-2568	the	place[119]	new[119]	coref	19-28[123_119]
19-16	2569-2576	frontal	place[119]	new[119]	_	_
19-17	2577-2583	cortex	place[119]	new[119]	_	_
19-18	2584-2585	,	_	_	_	_
19-19	2586-2589	but	_	_	_	_
19-20	2590-2600	muscarinic	substance[121]|abstract[122]	new[121]|new[122]	_	_
19-21	2601-2614	acetylcholine	substance|substance[121]|abstract[122]	giv|new[121]|new[122]	coref	23-5
19-22	2615-2623	receptor	substance[121]|abstract[122]	new[121]|new[122]	_	_
19-23	2624-2626	M1	abstract[122]	new[122]	_	_
19-24	2627-2630	was	_	_	_	_
19-25	2631-2640	gradually	_	_	_	_
19-26	2641-2649	depleted	_	_	_	_
19-27	2650-2652	in	_	_	_	_
19-28	2653-2661	cerebral	place[123]	giv[123]	_	_
19-29	2662-2668	cortex	place[123]	giv[123]	_	_
19-30	2669-2670	,	_	_	_	_
19-31	2671-2679	striatum	object	new	_	_
19-32	2680-2683	and	_	_	_	_
19-33	2684-2695	hippocampus	object[125]	new[125]	_	_
19-34	2696-2700	that	object[125]	new[125]	_	_
19-35	2701-2704	are	object[125]	new[125]	_	_
19-36	2705-2713	involved	object[125]	new[125]	_	_
19-37	2714-2716	in	object[125]	new[125]	_	_
19-38	2717-2726	cognitive	object[125]|abstract[126]	new[125]|new[126]	coref	23-5[149_126]
19-39	2727-2735	function	object[125]|abstract[126]	new[125]|new[126]	_	_
19-40	2736-2737	.	_	_	_	_

#Text=In addition , in stroke patients , reduced AChE activity was correlated with lower survival rate .
20-1	2738-2740	In	_	_	_	_
20-2	2741-2749	addition	_	_	_	_
20-3	2750-2751	,	_	_	_	_
20-4	2752-2754	in	_	_	_	_
20-5	2755-2761	stroke	event|person[128]	giv|giv[128]	coref|coref	21-14|22-12[145_128]
20-6	2762-2770	patients	person[128]	giv[128]	_	_
20-7	2771-2772	,	_	_	_	_
20-8	2773-2780	reduced	abstract[130]	giv[130]	coref	24-44[0_130]
20-9	2781-2785	AChE	abstract|abstract[130]	giv|giv[130]	coref	21-8
20-10	2786-2794	activity	abstract[130]	giv[130]	_	_
20-11	2795-2798	was	_	_	_	_
20-12	2799-2809	correlated	_	_	_	_
20-13	2810-2814	with	_	_	_	_
20-14	2815-2820	lower	abstract[132]	new[132]	_	_
20-15	2821-2829	survival	event|abstract[132]	new|new[132]	_	_
20-16	2830-2834	rate	abstract[132]	new[132]	_	_
20-17	2835-2836	.	_	_	_	_

#Text=Taken together , these results suggest that AChE dysfunction is a result of stroke rather than a cause for further neurodegeneration .
21-1	2837-2842	Taken	_	_	_	_
21-2	2843-2851	together	_	_	_	_
21-3	2852-2853	,	_	_	_	_
21-4	2854-2859	these	abstract[133]	new[133]	_	_
21-5	2860-2867	results	abstract[133]	new[133]	_	_
21-6	2868-2875	suggest	_	_	_	_
21-7	2876-2880	that	_	_	_	_
21-8	2881-2885	AChE	abstract|abstract[135]	giv|giv[135]	coref	22-3
21-9	2886-2897	dysfunction	abstract[135]	giv[135]	_	_
21-10	2898-2900	is	_	_	_	_
21-11	2901-2902	a	_	_	_	_
21-12	2903-2909	result	_	_	_	_
21-13	2910-2912	of	_	_	_	_
21-14	2913-2919	stroke	event	giv	coref	22-9
21-15	2920-2926	rather	_	_	_	_
21-16	2927-2931	than	_	_	_	_
21-17	2932-2933	a	abstract[137]	giv[137]	_	_
21-18	2934-2939	cause	abstract[137]	giv[137]	_	_
21-19	2940-2943	for	abstract[137]	giv[137]	_	_
21-20	2944-2951	further	abstract[137]|abstract[138]	giv[137]|new[138]	_	_
21-21	2952-2969	neurodegeneration	abstract[137]|abstract[138]	giv[137]|new[138]	_	_
21-22	2970-2971	.	_	_	_	_

#Text=Moreover , AChE inhibitors exert no effect on stroke risk in dementia patients .
22-1	2972-2980	Moreover	_	_	_	_
22-2	2981-2982	,	_	_	_	_
22-3	2983-2987	AChE	abstract|substance[140]	giv|giv[140]	coref	23-7
22-4	2988-2998	inhibitors	substance[140]	giv[140]	_	_
22-5	2999-3004	exert	_	_	_	_
22-6	3005-3007	no	abstract[141]	new[141]	_	_
22-7	3008-3014	effect	abstract[141]	new[141]	_	_
22-8	3015-3017	on	abstract[141]	new[141]	_	_
22-9	3018-3024	stroke	abstract[141]|event|abstract[143]	new[141]|giv|giv[143]	coref	25-31[181_0]
22-10	3025-3029	risk	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
22-11	3030-3032	in	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
22-12	3033-3041	dementia	abstract[141]|abstract[143]|abstract|person[145]	new[141]|giv[143]|giv|giv[145]	coref	24-46[169_145]
22-13	3042-3050	patients	abstract[141]|abstract[143]|person[145]	new[141]|giv[143]|giv[145]	_	_
22-14	3051-3052	.	_	_	_	_

#Text=These observations suggest that Ach and AChE function may predict post-stroke neuronal damage .
23-1	3053-3058	These	abstract[146]	new[146]	_	_
23-2	3059-3071	observations	abstract[146]	new[146]	_	_
23-3	3072-3079	suggest	_	_	_	_
23-4	3080-3084	that	_	_	_	_
23-5	3085-3088	Ach	substance|abstract[149]	giv|giv[149]	coref	25-2[172_0]
23-6	3089-3092	and	abstract[149]	giv[149]	_	_
23-7	3093-3097	AChE	abstract|abstract[149]	giv|giv[149]	coref	25-7
23-8	3098-3106	function	abstract[149]	giv[149]	_	_
23-9	3107-3110	may	_	_	_	_
23-10	3111-3118	predict	_	_	_	_
23-11	3119-3130	post-stroke	abstract[150]	giv[150]	_	_
23-12	3131-3139	neuronal	abstract[150]	giv[150]	_	_
23-13	3140-3146	damage	abstract[150]	giv[150]	_	_
23-14	3147-3148	.	_	_	_	_

#Text=To date , only a few blood biomarkers for predicting PSD have been examined ( e.g. , D-amino acid oxidase , β-secretase , and inflammation markers ) , and few studies have focused on changes in blood cholinesterase ( ChE ) levels and activity in patients with PSD .
24-1	3149-3151	To	_	_	_	_
24-2	3152-3156	date	time	new	_	_
24-3	3157-3158	,	_	_	_	_
24-4	3159-3163	only	abstract[153]	new[153]	_	_
24-5	3164-3165	a	abstract[153]	new[153]	_	_
24-6	3166-3169	few	abstract[153]	new[153]	_	_
24-7	3170-3175	blood	substance|abstract[153]	new|new[153]	coref	24-37
24-8	3176-3186	biomarkers	abstract[153]	new[153]	_	_
24-9	3187-3190	for	abstract[153]	new[153]	_	_
24-10	3191-3201	predicting	abstract[153]	new[153]	_	_
24-11	3202-3205	PSD	abstract[153]|person	new[153]|giv	coref	24-48
24-12	3206-3210	have	_	_	_	_
24-13	3211-3215	been	_	_	_	_
24-14	3216-3224	examined	_	_	_	_
24-15	3225-3226	(	_	_	_	_
24-16	3227-3231	e.g.	substance[157]	new[157]	_	_
24-17	3232-3233	,	substance[157]	new[157]	_	_
24-18	3234-3241	D-amino	substance|substance[156]|substance[157]	new|new[156]|new[157]	_	_
24-19	3242-3246	acid	substance[156]|substance[157]	new[156]|new[157]	_	_
24-20	3247-3254	oxidase	substance[157]	new[157]	_	_
24-21	3255-3256	,	_	_	_	_
24-22	3257-3268	β-secretase	substance	new	_	_
24-23	3269-3270	,	_	_	_	_
24-24	3271-3274	and	_	_	_	_
24-25	3275-3287	inflammation	abstract|abstract[160]	giv|new[160]	_	_
24-26	3288-3295	markers	abstract[160]	new[160]	_	_
24-27	3296-3297	)	_	_	_	_
24-28	3298-3299	,	_	_	_	_
24-29	3300-3303	and	_	_	_	_
24-30	3304-3307	few	abstract[161]	giv[161]	_	_
24-31	3308-3315	studies	abstract[161]	giv[161]	_	_
24-32	3316-3320	have	_	_	_	_
24-33	3321-3328	focused	_	_	_	_
24-34	3329-3331	on	_	_	_	_
24-35	3332-3339	changes	abstract[162]	giv[162]	_	_
24-36	3340-3342	in	abstract[162]	giv[162]	_	_
24-37	3343-3348	blood	abstract[162]|substance|abstract[164]|abstract[166]|abstract[167]	giv[162]|giv|giv[164]|giv[166]|giv[167]	appos|coref	24-40[0_164]|24-37[167_166]
24-38	3349-3363	cholinesterase	abstract[162]|abstract[164]|abstract[166]|abstract[167]	giv[162]|giv[164]|giv[166]|giv[167]	_	_
24-39	3364-3365	(	abstract[162]|abstract[166]|abstract[167]	giv[162]|giv[166]|giv[167]	_	_
24-40	3366-3369	ChE	abstract[162]|abstract|abstract[166]|abstract[167]	giv[162]|giv|giv[166]|giv[167]	_	_
24-41	3370-3371	)	abstract[162]|abstract[166]|abstract[167]	giv[162]|giv[166]|giv[167]	_	_
24-42	3372-3378	levels	abstract[162]|abstract[166]|abstract[167]	giv[162]|giv[166]|giv[167]	_	_
24-43	3379-3382	and	abstract[162]|abstract[167]	giv[162]|giv[167]	_	_
24-44	3383-3391	activity	abstract[162]|abstract[167]|abstract	giv[162]|giv[167]|giv	_	_
24-45	3392-3394	in	_	_	_	_
24-46	3395-3403	patients	person[169]	giv[169]	coref	25-29[180_169]
24-47	3404-3408	with	person[169]	giv[169]	_	_
24-48	3409-3412	PSD	person[169]|person	giv[169]|giv	_	_
24-49	3413-3414	.	_	_	_	_

#Text=Since plasma Ach is metabolized by AChE and butylcholinesterase ( BChE ) , the present study examined the functional activities of these two enzymes in a population of patients with chronic ischemic stroke ( IS ) .
25-1	3415-3420	Since	_	_	_	_
25-2	3421-3427	plasma	substance|substance[172]	new|giv[172]	_	_
25-3	3428-3431	Ach	substance[172]	giv[172]	_	_
25-4	3432-3434	is	_	_	_	_
25-5	3435-3446	metabolized	_	_	_	_
25-6	3447-3449	by	_	_	_	_
25-7	3450-3454	AChE	abstract	giv	_	_
25-8	3455-3458	and	_	_	_	_
25-9	3459-3478	butylcholinesterase	substance	new	_	_
25-10	3479-3480	(	_	_	_	_
25-11	3481-3485	BChE	abstract	new	_	_
25-12	3486-3487	)	_	_	_	_
25-13	3488-3489	,	_	_	_	_
25-14	3490-3493	the	abstract[176]	giv[176]	_	_
25-15	3494-3501	present	abstract[176]	giv[176]	_	_
25-16	3502-3507	study	abstract[176]	giv[176]	_	_
25-17	3508-3516	examined	_	_	_	_
25-18	3517-3520	the	abstract[177]	new[177]	_	_
25-19	3521-3531	functional	abstract[177]	new[177]	_	_
25-20	3532-3542	activities	abstract[177]	new[177]	_	_
25-21	3543-3545	of	abstract[177]	new[177]	_	_
25-22	3546-3551	these	abstract[177]|abstract[178]	new[177]|new[178]	_	_
25-23	3552-3555	two	abstract[177]|abstract[178]	new[177]|new[178]	_	_
25-24	3556-3563	enzymes	abstract[177]|abstract[178]	new[177]|new[178]	_	_
25-25	3564-3566	in	abstract[177]|abstract[178]	new[177]|new[178]	_	_
25-26	3567-3568	a	abstract[177]|abstract[178]|person[179]	new[177]|new[178]|new[179]	_	_
25-27	3569-3579	population	abstract[177]|abstract[178]|person[179]	new[177]|new[178]|new[179]	_	_
25-28	3580-3582	of	abstract[177]|abstract[178]|person[179]	new[177]|new[178]|new[179]	_	_
25-29	3583-3591	patients	abstract[177]|abstract[178]|person[179]|person[180]	new[177]|new[178]|new[179]|giv[180]	_	_
25-30	3592-3596	with	abstract[177]|abstract[178]|person[179]|person[180]	new[177]|new[178]|new[179]|giv[180]	_	_
25-31	3597-3604	chronic	abstract[177]|abstract[178]|person[179]|person[180]|event[181]	new[177]|new[178]|new[179]|giv[180]|giv[181]	_	_
25-32	3605-3613	ischemic	abstract[177]|abstract[178]|person[179]|person[180]|event[181]	new[177]|new[178]|new[179]|giv[180]|giv[181]	_	_
25-33	3614-3620	stroke	abstract[177]|abstract[178]|person[179]|person[180]|event[181]	new[177]|new[178]|new[179]|giv[180]|giv[181]	_	_
25-34	3621-3622	(	_	_	_	_
25-35	3623-3625	IS	abstract	new	_	_
25-36	3626-3627	)	_	_	_	_
25-37	3628-3629	.	_	_	_	_
